859 research outputs found
CAR: A MATLAB Package to Compute Correspondence Analysis with Rotations
Correspondence analysis (CA) is a popular method that can be used to analyse relationships between categorical variables. Like principal component analysis, CA solutions can be rotated both orthogonally and obliquely to simple structure without affecting the total amount of explained inertia. We describe a MATLAB package for computing CA. The package includes orthogonal and oblique rotation of axes. It is designed not only for advanced users of MATLAB but also for beginners. Analysis can be done using a user-friendly interface, or by using command lines. We illustrate the use of CAR with one example.
Measuring soccer players’ contributions to chance creation by valuing their passes
Scouting departments at soccer clubs aim to discover players having a positive influence on the outcomes
of matches. Since passes are the most frequently occurring on-the-ball actions on the pitch, a natural way to
achieve this objective is by identifying players who are
effective in setting up chances. Unfortunately, traditional
statistics such as number of assists fail to reveal players
excelling in this area. To overcome this limitation, this
paper introduces a novel metric that measures the players’
involvement in setting up chances by valuing the effectiveness of their passes. Our proposed metric identifies
Arsenal player Mesut Özil as the most impactful player in
terms of passes during the 2017/2018 season and proposes
Ajax player Frenkie de Jong as a suitable replacement for
Andrés Iniesta at FC Barcelona
Assessment of carnitine excretion and its ratio to plasma free carnitine as a biomarker for primary carnitine deficiency in newborns
In the Netherlands, newborns are referred by the newborn screening (NBS) Program when a low free carnitine (C0) concentration (<5 μmol/l) is detected in their NBS dried blood spot. This leads to ~85% false positive referrals who all need an invasive, expensive and lengthy evaluation. We investigated whether a ratio of urine C0 / plasma C0 (RatioU:P) can improve the follow-up protocol for primary carnitine deficiency (PCD). A retrospective study was performed in all Dutch metabolic centres, using samples from newborns and mothers referred by NBS due to low C0 concentration. Samples were included when C0 excretion and plasma C0 concentration were sampled on the same day. RatioU:P was calculated as (urine C0 [μmol/mmol creatinine])/(plasma C0 [μmol/l]). Data were available for 59 patients with genetically confirmed PCD and 68 individuals without PCD. The RatioU:P in PCD patients was significantly higher (p value < 0.001) than in those without PCD, median [IQR], respectively: 3.4 [1.2–9.5], 0.4 [0.3–0.8], area under the curve (AUC) 0.837. Classified for age (up to 1 month) and without carnitine suppletion (PCD; N = 12, Non-PCD; N = 40), medians were 6.20 [4.4–8.8] and 0.37 [0.24–0.56], respectively. The AUC for RatioU:P was 0.996 with a cut-off required for 100% sensitivity at 1.7 (yielding one false positive case). RatioU:P accurately discriminates between positive and false positive newborn referrals for PCD by NBS. RatioU:P is less effective as a discriminative tool for PCD in adults and for individuals that receive carnitine suppletion.</p
Orthogonal rotation in PCAMIX
Kiers (1991) considered the orthogonal rotation in PCAMIX, a principal
component method for a mixture of qualitative and quantitative variables.
PCAMIX includes the ordinary principal component analysis (PCA) and multiple
correspondence analysis (MCA) as special cases. In this paper, we give a new
presentation of PCAMIX where the principal components and the squared loadings
are obtained from a Singular Value Decomposition. The loadings of the
quantitative variables and the principal coordinates of the categories of the
qualitative variables are also obtained directly. In this context, we propose a
computationaly efficient procedure for varimax rotation in PCAMIX and a direct
solution for the optimal angle of rotation. A simulation study shows the good
computational behavior of the proposed algorithm. An application on a real data
set illustrates the interest of using rotation in MCA. All source codes are
available in the R package "PCAmixdata"
Расчёт напряженно-деформированного состояния виброизоляторов сложной формы
Розглянуто пружно-деформований стан гумових віброізоляторів з урахуванням контактної взаємодії з деталями конструкції.Stress-strain state of rubber vibroinsulators is considered, taking into account contact interaction with construction parts
Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands:the OCEAN study
Contains fulltext :
229349.pdf (Publisher’s version ) (Closed access
Three years of growth hormone treatment in young adults with Prader-Willi Syndrome previously treated with growth hormone in childhood: Effects on glucose homeostasis and metabolic syndrome
Context: Growth hormone (GH) has been approved for children with Prader-Willi syndrome (PWS) and significantly improves body composition in adults with PWS. Adults with PWS are predisposed to develop impaired glucose tolerance (IGT) and diabetes mellitus type 2 (DMT2). Continuation of GH maintains body composition, but GH is known to induce insulin resistance, which might affect glucose homeostasis. Studies on long-term effects of GH treatment in adults are very limited. Objective: To investigate effects of 3 years of GH treatment on glucose homeostasis and prevalence of metabolic syndrome (MS) in adults with PWS. Design: Open-label, prospective study. Patients: 43 young adults with PWS. Setting: Dutch PWS Reference Center. Main outcome measures: Glucose and insulin during oral glucose tolerance test. Results: Estimated mean (95% CI) fasting glucose and insulin levels remained stable during 3 years of GH treatment. Glucose being 4.6 (4.4-4.8) mmol/l at start and 4.7 (4.6-4.9) mmol/l after 3 years (P =.07); insulin being 59.5 (45.2-75.8) pmol/l and 56.7 (45.2-69.6) pmol/l resp. (P =.72). Sex, ethnicity and fat mass percentage were significantly associated with fasting glucose levels, while IGF-I or GH-dose were not. Blood pressure, lipids and prevalence of MS remained stable during 3 years of GH. IGT prevalence was variable over time, six patients had IGT at start and eleven after 3 years of GH. One patient developed DMT2. However, prevalence of IGT or DMT2 was not significantly higher after 3 years than at study start. Conclusions: Three years of GH treatment in adults with PWS does not impair glucose homeostasis and does not lead to an increased prevalence of DMT2
Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization
Gemtuzumab ozogamicin (GO) is a chemotherapy-conjugated anti-CD33 monoclonal antibody effective in some patients with acute myeloid leukemia (AML). The optimal treatment schedule and optimal timing of GO administration relative to other agents remains unknown. Conventional pharmacokinetic analysis has been of limited insight for the schedule optimization. We developed a mechanism-based mathematical model and employed it to analyze the time-course of free and GO-bound CD33 molecules on the lekemic blasts in individual AML patients treated with GO. We calculated expected intravascular drug exposure (I-AUC) as a surrogate marker for the response to the drug. A high CD33 production rate and low drug efflux were the most important determinants of high I-AUC, characterizing patients with favorable pharmacokinetic profile and, hence, improved response. I-AUC was insensitive to other studied parameters within biologically relevant ranges, including internalization rate and dissociation constant. Our computations suggested that even moderate blast burden reduction prior to drug administration enables lowering of GO doses without significantly compromising intracellular drug exposure. These findings indicate that GO may optimally be used after cyto-reductive chemotherapy, rather than before, or concomitantly with it, and that GO efficacy can be maintained by dose reduction to 6 mg/m2 and a dosing interval of 7 days. Model predictions are validated by comparison with the results of EORTC-GIMEMA AML19 clinical trial, where two different GO schedules were administered. We suggest that incorporation of our results in clinical practice can serve identification of the subpopulation of elderly patients who can benefit most of the GO treatment and enable return of the currently suspended drug to clinic
- …